Lamina

Lamina Therapeutics is a clinical-stage biotechnology company headquartered in Strasbourg, France, focused on the development of innovative regenerative medicine solutions for bone and cartilage repair. Founded in 2020 as a spin-off from INSERM and the University of Strasbourg, the company leverages over a decade of research in nanotechnology and tissue engineering. Its flagship platform, Lamina.One, is a combined advanced therapy medicinal product (cATMP) that integrates a functionalized, biodegradable polymeric membrane with nanostructured reservoirs for controlled drug release and autologous mesenchymal stem cells. This dual-action approach is designed to simultaneously regenerate subchondral bone and articular cartilage, addressing significant unmet needs in the treatment of knee osteochondral lesions and osteoarthritis. Lamina Therapeutics is currently conducting Phase I clinical trials to validate the safety and efficacy of its lead candidate.